Company performance
Add to research
Current Price
as of Apr 17, 2025$1.31
P/E Ratio
N/A
Market Cap
$13.71M
Description
Add to research
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Metrics
Add to research
Overview
- HQLexington, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerCRIS
- Price$1.31+1.55%
Trading Information
- Market cap$13.71M
- Float88.19%
- Average Daily Volume (1m)97,329
- Average Daily Volume (3m)53,329
- EPS-$6.88
Company
- Revenue$10.91M
- Rev growth (1yr)8.83%
- Net income-$43.39M
- Gross margin97.24%
- EBITDA margin-400.98%
- EBITDA-$43.74M
- EV$36.43M
- EV/Revenue3.34
- P/EN/A
- P/S0.76
- P/BN/A
- Debt/EquityN/A
Documents
Add to research
SEC Filings
Factset Street Account